SMMT
USDSummit Therapeutics Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$17.780
Максимум
$18.120
Минимум
$17.370
Объем
2.88M
Фундаментальные показатели компании
Рыночная капитализация
13.0B
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
4.10M
Биржа
NGM
Валюта
USD
52-недельный диапазон
Связанные новости
Summit Therapeutics to Present at Upcoming Investor Conferences
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
Guggenheim analyst Brad Canino reiterates Summit Therapeutics with a Buy and maintains $40 price target.
Summit Therapeutics Raises $500 Million in Private Placement
Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit,"
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
Barclays analyst Etzer Darout maintains Summit Therapeutics with a Underweight and raises the price target from $13 to $16.
HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics with a Buy and lowers the price target from $50 to $40.
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Conference Call to be Held at 8:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.